Youyan Zhang

Zhejiang Normal University — China

Biochemistry, Genetics and Molecular Biology · Life Sciences

29h-index3.7kcitations122works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(18), Advanced Wireless Communication Techniques(12), Colorectal Cancer Treatments and Studies(12), Cholesterol and Lipid Metabolism(11), Protein Kinase Regulation and GTPase Signaling(9)

Publications122 total

GATE-Fusion: GBDT Attention-based Tree Embedding for Financial Risk Prediction
2025Open Access
Extraction of Tree Diameter at Breast Height Using UAV-based Point Cloud Data
2025
Abstract 4375: LY4066434, an oral small molecule pan-KRAS inhibitor, demonstrates robust anti-tumor activity in KRAS-mutant models, including in the CNS
Cancer Research·2025· 2 cited
REP Node Modification and Fast Decoding of Multi-Kernel Polar Codes Constructed with a New 5 × 5 Kernel
IEICE Transactions on Communications·2025
An Improvement of the Weight Distribution of Polar Codes
IEICE Transactions on Fundamentals of Electronics Communications and Computer Sciences·2025· 1 citedOpen Access
REP node modification and fast decoding of new 5×5 kernel polar codes
2024
Abstract 3316: LY3962673, an oral, highly potent, mutant-selective, and non-covalent KRAS G12D inhibitor demonstrates robust anti-tumor activity in KRAS G12D models
Cancer Research·2024· 7 cited
Design polar codes with large kernels based on reciprocal channel approximation
2023
A trellis decoding based on Massey trellis for polar codes with a ternary kernel
2023· 1 cited
Design polar codes with 3×3 kernel matrix based on piecewise Gaussian approximation
2023
Multi-stack decoding Algorithm for Polarization-adjusted Convolutional Codes
2023· 2 cited
A soft-output stack decoding of polarization-adjusted convolutional codes
2023· 2 cited
Supplementary Figures S1 - S7, Tables S1 - S2 from Oncogenic <i>BRAF</i> Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120
2023Open Access
Data from Oncogenic <i>BRAF</i> Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120
2023Open Access
Supplementary Figures S1-S4 from The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
2023Open Access
Supplementary Figures S1 - S7, Tables S1 - S2 from Oncogenic <i>BRAF</i> Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120
2023Open Access
Supplementary Table S1 and Supplementary Figure Legends from The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
2023Open Access
Data from Oncogenic <i>BRAF</i> Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120
2023Open Access
Data from The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
2023Open Access
Supplementary Table S1 and Supplementary Figure Legends from The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Robert J. Schmidt(13), Thomas P. Beyer(13), Guoqing Cao(11), Patrick I. Eacho(10), Guoqing Cao(8), Sheng-Bin Peng(7), Xian‐Cheng Jiang(7), James R. Henry(5), Robert D. Van Horn(5), Lysiane Huber(5), Jinhua Cheng(5), Vipin Yadav(4), Xueqian Gong(4), Sean G. Buchanan(4), James J. Starling(4), Hong Gao(4), Thomas P. Burris(4), William R. Bensch(4), Robert J. Konrad(4), Kevin Shannon(4)